TRPM3

TRPM3

Pipeline Innovation Engine Clinical Trials at Biohaven Publications

FIRST-IN-CLASS TRPM3 ANTAGONIST FOR MIGRAINE AND PAIN

BHV-2100 is Biohaven’s first-in-class molecule directed against TRPM3, a novel druggable calcium channel in the transient receptor potential (TRP) channel family.

BHV-2100 is a highly selective, potent, and peripherally-restricted TRPM3 antagonist that reverses pain in multiple preclinical...

Innovation Engine

Innovation Engine

Pipeline Innovation Engine Clinical Trials at Biohaven Publications

DEVELOPING NEXT-GENERATION BISPECIFIC COMPOUNDS AND INNOVATIVE THERAPIES

Biohaven is developing drug candidates based on its proprietary, next-generation bispecific technology platforms and other innovative approaches. These bispecific platforms are modular in design to enable rapid generation of novel therapies for the treatment of...

Innovation

Pipeline

Pipeline Innovation Engine Clinical Trials at Biohaven Publications

BIOHAVEN'S EXTENSIVE CLINICAL AND PRECLINICAL PROGRAMS

include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for antibody-mediated diseases; TRPM3 activation for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder; myostatin inhibition for neuromuscular...